Mankind Pharma Navigates Strategic Shifts and Strong Chronic Growth in Q3 FY26

Mankind Pharma Limited, a prominent player in the Indian pharmaceutical landscape, has reported its financial performance for the third quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26). The company showcased a resilient performance, with revenue from operations increasing by 11.5% year-on-year to INR 3,567 crore in Q3 FY26. Adjusted EBITDA margins stood at 25.9%, primarily bolstered by improvements in the domestic pharma segment and the consolidation of BSV. For the nine-month period, revenue grew by an impressive 18.7% year-on-year, reaching INR 10,835 crore, with adjusted EBITDA margins at 24.9%. This period has been pivotal for Mankind Pharma, marked by significant internal transformations and strategic initiatives aimed at optimizing its brand portfolio and expanding market reach.

The company's domestic business recorded a robust year-on-year growth of 11.1% in Q3 FY26, driven by improved volume growth in its pharma segment and strong momentum in chronic performance, alongside contributions from the BSV domestic portfolio. The consumer healthcare business also saw a sequential growth momentum, with revenue increasing by 5.2% year-on-year in Q3 FY26, recovering from a decline in the previous quarter. Exports business demonstrated strong growth, increasing by 14.1% year-on-year to INR 521 crore in Q3 FY26, primarily fueled by the BSV international business. The company's chronic share in the domestic market expanded by 200 basis points year-on-year to 39.3%, propelled by strong growth in cardiac (16.7%) and anti-diabetes (14.4%) segments.

Strategic Initiatives and Operational Focus

Mankind Pharma has been actively pursuing several strategic initiatives to drive long-term sustainable growth. The company is focused on consolidating its market share in the increased CVM (Chronic, Vitamins, Minerals) segment, aiming for deeper penetration through volume-focused growth and brand scaling. A key strategic pillar is increasing its chronic share by expanding its presence in therapies such as Diabetes (Empagliflozin, Insulin Glargine), Respiratory (Inhalers), CNS, and Urology. The expansion into a super specialty portfolio, through M&As like the BSV acquisition and in-licensing agreements for high-entry barrier products (e.g., Symbicort, Inclisiran, Vonoprazan), is also a significant focus.

Operationally, the company is enhancing its penetration in Metros and Tier I cities by engaging Key Opinion Leaders (KOLs), establishing hospital tie-ups, and launching specialty divisions. It is also launching DMF grade products and building alternative growth channels, including modern trade. The consumer healthcare business is being strengthened by leveraging existing brand equity and exploring new distribution models, including Rx to OTx to OTC transitions. Furthermore, Mankind Pharma is investing in digital platforms for enhanced productivity through AI/ML technologies and increasing its focus on R&D to expand into high-entry barrier complex products, leveraging the BSV R&D tech platform.

Management Commentary and Outlook

Management acknowledged that the internal transformation process, involving significant new hiring and cultural integration, took longer than initially anticipated (12-15 months), leading to some underperformance in acute segments. However, they expressed confidence that these corrective actions are now translating into gradual recovery, with workforce stability improving and teams gaining maturity. The company's overall PCPM (Per Capita Per Month) improved to INR 7.2 lakhs as of December 31, 2025, from INR 6.5 lakhs as of March 31, 2025.

Gross margins for the quarter increased by 170 basis points year-on-year to 72.6%, driven by sales price increases, favorable sales mix, and the release of inventory-related accruals. Finance costs decreased due to the repayment of commercial papers worth INR 1,500 crore in October 2025. The consolidated effective tax rate for 9M FY26 was lower at 17.6% compared to 21.2% in 9M FY25. The company's net debt to adjusted EBITDA ratio improved to 1.3x, reflecting a prudent financial strategy.

In conclusion, Mankind Pharma Limited is demonstrating strategic clarity and disciplined execution, navigating internal transformations while capitalizing on robust growth in its chronic and specialty segments. The management's focus on strengthening the balance sheet, optimizing the product portfolio, and expanding into high-potential areas positions the company for sustained long-term growth and enhanced shareholder value, despite acknowledging and addressing short-term operational challenges.